Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Research & Diagnostic Antibodies Receives Notice of Allowance for Sepsis Diagnostic Patent

Published: Thursday, August 09, 2012
Last Updated: Thursday, August 09, 2012
Bookmark and Share
Patent extends IP estate on plasma iNOS biomarker and covers iNOS immunoassays and apparatuses for early sepsis detection.

Research & Diagnostic Antibodies (R&D Antibodies) announced that it has received a Notice of Allowance from the Japan Patent Office for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology. Japanese Patent Application #2003-517204 covers very broadly the use of R&D Antibodies' immunoassays, assay kits, and apparatuses for the detection of plasma iNOS as an early biomarker for the prognosis and diagnosis of the life-threatening sepsis pathology. The JPO's Allowance extends R&D Antibodies' existing patent portfolio in this field (USA #6531578-B1 and 7198904-B1; European #EP1012605 and EP1412471; Japan #4117911; and Australian #2001280912 and 782922). Additional patent applications are pending.

Plasma iNOS is the foundation of R&D Antibodies' sepsis prognosis and monitoring tests that reveal very early the onset of the sepsis pathology. To date R&D Antibodies has conducted three clinical studies involving more than 295 ICU patients to demonstrate the utility of this new plasma biomarker. The last two clinical studies were partially funded by research grants awarded by the National Institutes of Health (NIH) after thorough peer review. R&D Antibodies is currently working on a $2.6 M grant awarded by the National Institute of General Medical Sciences to conduct a pivotal clinical study which should generate the data required to obtain FDA marketing clearance for this new blood test.

Plasma iNOS has been found to be a specific, accurate and reliable biomarker for detecting very early the onset of sepsis. This new test identifies those patients who will develop the sepsis pathology 24 - 48 hours prior to the appearance of the physiological symptoms currently used by physicians as indictors of the onset of sepsis. In a direct comparison with the Procalcitonin test (an FDA-approved test for sepsis), plasma iNOS was found to be more specific than PCT and to be an earlier biomarker for the onset of the sepsis pathology. Plasma iNOS as a biomarker was shown to predict accurately the onset of sepsis in more than 96% of the severely injured ICU patients studied.

"This patent continues to build our intellectual property estate and adds to our leadership position in the early detection of sepsis," said Dr. Robert Webber, Ph.D., President and CEO of R&D Antibodies, and the lead inventor on the patent. "Detection of circulating iNOS has broad application in numerous clinical settings including ICUs, emergency rooms, rehabilitation facilities, nursing homes, and outpatient clinics, and should guide physicians to initiate treatment earlier in this life-threatening pathology leading to reduced mortality and morbidity for the patient and reducing the huge financial drain that sepsis, severe sepsis and septic shock impose upon the healthcare system."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!